الانتقال إلى المحتوى الرئيسي
xMedica

NCT07624305ClinicalTrials.gov

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…

المرحلة 3مطلوب 2,800 مشارك478 موقعاً27 دولة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.

How this score is built
  • Enrolment34/40

    2,800 participants (target)

  • Site count19/25

    45 sites

  • Country count12/15

    8 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale10/10

    AstraZeneca has led 999 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

This is a Phase III, multicentre, randomised, double-blind, double-dummy, parallel-group, active-controlled, event-driven study in participants with CKD Stage 3b and 4. The purpose of this study is to determine if balcinrenone/dapagliflozin, compared with dapagliflozin, administered as a capsule once daily on a background of standard of care (SoC) therapy, reduces the risk of CV death, death from kidney failure, kidney failure, sustained ≥ 50% decline from baseline in eGFR, and HF events in adults with CKD Stage 3b and 4. The study will also assess safety and tolerability of balcinrenone/dapagliflozin. Eligible patients will randomly be assigned with a 1:1 ratio to receive once daily administration of one capsule and one tablet of one of the following treatments: 1. Balcinrenone/dapagliflozin 15 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 2. Dapagliflozin 10 mg tablet and matching placebo for balcinrenone/dapagliflozin capsule The study will be conducted at approximately 550 sites in approximately 30 countries, globally.

الحالات

  • Renal Insufficiency, Chronic

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – 99 Years
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of CKD and at least one of the following: 1. eGFR ≥ 15 to \< 45 mL/min/1.73 m2 AND: UACR ≥ 30 mg/g (central laboratory) or UACR ≥ 100 mg/g (local laboratory ) or UPCR ≥ 200 mg/g (local laboratory). 2. eGFR ≥ 15 to \< 30 mL/min/1.73 m2 and UACR \< 30 mg/g (local or central laboratory UACR value). * Serum/plasma K+ ≤ 5.0 mmol/L * Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening. Exclusion Criteria: * Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation * UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening. * SBP \> 180 mmHg or DBP \> 110 mmHg at screening. * SBP \< 90 mmHg at screening. * HbA1c \> 9% at screening * T1DM, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion. * Autosomal dominant polycystic kidney disease. * Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening. * Severe hepatic impairment (Child-Pugh Class C). * Adrenal insufficiency. * Clinically significant acute kidney injury within 12 weeks prior to the screening. * New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening. * Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening. * Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation. * Any use of the following medications and supplements: 1. MRAs 2. Aldosterone analogues 3. Aldosterone synthase inhibitors 4. Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation. 5. Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 2,800 مشارك

الجهة الراعية والمتعاونون

  • AstraZeneca الجهة الراعية

الأذرع والتدخلات

  • Balcinrenone/dapagliflozinEXPERIMENTAL

    Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.

  • DapagliflozinACTIVE_COMPARATOR

    Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.

التدخلات

  • دواء Balcinrenone/dapagliflozin

    balcinrenone/dapagliflozin 15 mg/10 mg

  • دواء Dapagliflozin

    dapagliflozin 10 mg

  • دواء Placebo matching Dapagliflozin

    matching placebo for dapagliflozin 10 mg

  • دواء Placebo matching balcinrenone/dapagliflozin

    matching placebo for balcinrenone/dapagliflozin

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation

    الإطار الزمني Up to 46 months.

  2. مقياس النتيجة الثانوي

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR

    الإطار الزمني Up to 46 months.

  3. مقياس النتيجة الثانوي

    Change in urinary albumin to creatinine ratio to Week 24

    Change from baseline to Week 24 in urinary albumin to creatinine ratio

    الإطار الزمني Baseline to Week 24

  4. مقياس النتيجة الثانوي

    Time to first occurrence of cardiovascular death or heart failure event.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation

    الإطار الزمني Up to 46 months.

  5. مقياس النتيجة الثانوي

    Time to cardiovascular death

    Time from randomization to cardiovascular death.

    الإطار الزمني Up to 46 months.

  6. مقياس النتيجة الثانوي

    Time to death from any cause

    Time from randomization to death from any cause.

    الإطار الزمني Up to 46 months.

التواريخ

التواريخ
تاريخ البدء1 سبتمبر 2026 (فعلي)
الإتمام الأولي1 يوليو 2030 (تقديري)
الإتمام1 يوليو 2030 (تقديري)
أول نشر3 يونيو 2026 (فعلي)
آخر تحديث24 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

33 موقعاً قيد التجنيد

Argentina

Argentina
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteCABAلم يبدأ التجنيد بعد
Research SiteCapital Federalلم يبدأ التجنيد بعد
Research SiteCiudad de Buenos Airesلم يبدأ التجنيد بعد
Research SiteLa Plataلم يبدأ التجنيد بعد
Research SiteLanús Esteلم يبدأ التجنيد بعد
Research SiteMar del Plataلم يبدأ التجنيد بعد
Research SiteRosarioلم يبدأ التجنيد بعد
Research SiteRosarioلم يبدأ التجنيد بعد
Research SiteRosarioلم يبدأ التجنيد بعد
Research SiteSan Nicolásلم يبدأ التجنيد بعد
Research SiteSanta Feلم يبدأ التجنيد بعد
Research SiteSanta Feلم يبدأ التجنيد بعد

Austria

Austria
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteFeldkirchلم يبدأ التجنيد بعد
Research SiteInnsbruckلم يبدأ التجنيد بعد
Research SiteLinzلم يبدأ التجنيد بعد
Research SiteSankt Pöltenلم يبدأ التجنيد بعد
Research SiteViennaلم يبدأ التجنيد بعد
Research SiteViennaلم يبدأ التجنيد بعد
Research SiteViennaلم يبدأ التجنيد بعد
Research SiteViennaلم يبدأ التجنيد بعد
Research SiteWelsلم يبدأ التجنيد بعد
Research SiteWiener Neustadtلم يبدأ التجنيد بعد

Brazil

Brazil
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBarretosلم يبدأ التجنيد بعد
Research SiteBelo Horizonteلم يبدأ التجنيد بعد
Research SiteBelo Horizonteلم يبدأ التجنيد بعد
Research SiteBelémلم يبدأ التجنيد بعد
Research SiteCampinasلم يبدأ التجنيد بعد
Research SiteGoiâniaلم يبدأ التجنيد بعد
Research SiteNatalلم يبدأ التجنيد بعد
Research SiteRecifeلم يبدأ التجنيد بعد
Research SiteSão Caetano do Sulلم يبدأ التجنيد بعد
Research SiteSão José do Rio Pretoلم يبدأ التجنيد بعد
Research SiteSão José dos Camposلم يبدأ التجنيد بعد
Research SiteSão Pauloلم يبدأ التجنيد بعد
Research SiteSão Pauloلم يبدأ التجنيد بعد
Research SiteSão Pauloلم يبدأ التجنيد بعد
Research SiteSão Pauloلم يبدأ التجنيد بعد

Bulgaria

Bulgaria
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBlagoevgradلم يبدأ التجنيد بعد
Research SiteNova Zagoraلم يبدأ التجنيد بعد
Research SitePlevenلم يبدأ التجنيد بعد
Research SitePlovdivلم يبدأ التجنيد بعد
Research SiteSandanskiلم يبدأ التجنيد بعد
Research SiteSevlievoلم يبدأ التجنيد بعد
Research SiteSofiaلم يبدأ التجنيد بعد
Research SiteSofiaلم يبدأ التجنيد بعد
Research SiteSofiaلم يبدأ التجنيد بعد
Research SiteStara Zagoraلم يبدأ التجنيد بعد
Research SiteVarnaلم يبدأ التجنيد بعد

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBramptonOntarioلم يبدأ التجنيد بعد
Research SiteCalgaryAlbertaمسحوب

يُدرَج 428 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 24 سبتمبر 2026

    تغيّرت الحالة

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 24 سبتمبر 2026

    فُتح التجنيد

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. 24 سبتمبر 2026

    أُضيف موقع

    433 sites added (478 total)

    45478